TerminatedPhase 2NCT03960554
The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
Studying Idiopathic pregnancy-associated osteoporosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Thomas Nickolas, MD MS
- Principal Investigator
- Thomas Nickolas, MD, MSColumbia University
- Intervention
- Denosumab Inj 60 mg/ml(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2021
Study locations (3)
- Northwestern University, Feinburg School of Medicine, Chicago, Illinois, United States
- NorthShore University HealthSystem, Evanston, Illinois, United States
- Columbia University Medical Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03960554 on ClinicalTrials.govOther trials for Idiopathic pregnancy-associated osteoporosis
Additional recruiting or active studies for the same condition.
See all trials for Idiopathic pregnancy-associated osteoporosis →